AB

Absci CorpNASDAQ ABSI Stock Report

Last reporting period 30 Sep, 2024

Updated 02 Dec, 2024

Last price

Market cap $B

0.45

Micro

Exchange

XNAS - Nasdaq

ABSI Stock Analysis

AB

Uncovered

Absci Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-39/100

Low score

Market cap $B

0.45

Dividend yield

Shares outstanding

92.395 B

Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. The Company applies generative AI to design optimal drug candidates based on target affinity, safety, manufacturability, and other traits.

View Section: Eyestock Rating